Bipolar disorder: A landmark RCT (n=75) found that NAC (1,000 mg twice daily for 24 weeks) produced a significant improvement in depression scores (Montgomery-Asberg Depression Rating Scale) in bipolar disorder as an adjunct to usual treatment (Berk et al., Biol Psychiatry, 2008) [74]
The label expansion follows the FDAs March 2025 approval of an expanded label for lutetium Lu-177 vipivotide tetraxetan (Pluvicto) for use in patients with metastatic castration-resistant prostate cancer after treatment with an androgen receptor pathway inhibitor and before chemotherapy
Alright, thats enough political stuff you guys probably get enough of that elsewhere
This phase of growth will be shaped by rapid expansion in treatment access through private insurance and self-pay channels, increasing clinical adoption for cardiovascular risk reduction, and growing physician confidence in long-term safety profiles
Secondary adrenal insufficiency caused by emerging immunotherapies such as monoclonal antibody targeting programmed cell death protein 1 (PD-1